Bausch + Lomb Corp Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bausch + Lomb Corporation on April 10, 2023, regarding events reported on April 12, 2023. The filing addresses significant changes in executive leadership within the Ophthalmic Pharmaceuticals division and the legal department.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Departure: Christina M. Ackermann is departing as Executive Vice President & General Counsel and President, Ophthalmic Pharmaceuticals. Her employment ends effective April 28, 2023.
- Appointments: Effective April 24, 2023, A. Robert D. Bailey is appointed as Executive Vice President & Chief Legal Officer, and Andrew Stewart is appointed as President, Ophthalmic Pharmaceuticals.
Management Commentary and Background
Management highlighted the extensive experience of the incoming executives:
- A. Robert D. Bailey: Brings over 25 years of senior executive experience and more than 15 years as a chief legal officer in the health care industry. He previously served at Bausch + Lomb (2007-2013), Allergan plc, and most recently as Chief Legal Officer at Datavant.
- Andrew Stewart: Possesses over 25 years of pharmaceutical industry experience. He joins from AbbVie, where he served as general manager within the Eye Care franchise and previously led global marketing and business development for the Eye Care franchise at AbbVie and Allergan plc.
Key Facts for Investor Verification
- Confirm the effective dates of the leadership transition (April 24, 2023 for appointments; April 28, 2023 for departure).
- Review the attached Press Release (Exhibit 99.1) for additional details on the strategic rationale for these changes.
- Monitor future filings for any potential severance agreements or compensation arrangements related to Ms. Ackermann's departure, as specific financial terms are not detailed in this summary text.